Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Moderate to Severe Allergic Asthma (EDURO)
NCT04195958Phase 4Terminated
- Sponsor
- Genentech
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Genentech. Primary endpoint: Change From Baseline in Endurance Time During Cardiopulmonary Exercise Testing (CPET) at 24 weeks. Started Nov 2020; status: terminated.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT04195958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04195958.